Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05563220




Registration number
NCT05563220
Ethics application status
Date submitted
22/09/2022
Date registered
3/10/2022
Date last updated
2/05/2025

Titles & IDs
Public title
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Scientific title
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Secondary ID [1] 0 0
STML-ELA-0222
Universal Trial Number (UTN)
Trial acronym
ELEVATE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Metastatic Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Elacestrant
Treatment: Drugs - Alpelisib
Treatment: Drugs - Everolimus
Treatment: Drugs - Ribociclib
Treatment: Drugs - Palbociclib
Treatment: Drugs - Capivasertib
Treatment: Drugs - Abemaciclib

Experimental: Phase 1b Arm A: elacestrant with alpelisib - Elacestrant Dihydrochloride 300 mg or 400 mg + Alpelisib 250 mg or 300 mg

Experimental: Phase 1b Arm B: elacestrant with everolimus - Elacestrant Dihydrochloride 300 mg or 400 mg + Everolimus 5.0 mg, 7.5 mg or possibly 10 mg

Experimental: Phase 1b Arm C: elacestrant with abemaciclib or ribociclib: - Elacestrant Dihydrochloride 100 mg, 200 mg, 300 mg + Ribociclib 400 mg or possibly 600 mg

The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)

Experimental: Phase 1b Arm D: elacestrant with either palbociclib, abemaciclib, or ribociclib (no prior CDK4/6i) - Elacestrant Dihydrochloride 300 mg or 400 mg + Palbociclib 100 mg,125 mg OR The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)

Elacestrant 86 mg, 172 mg, 258 mg + Ribociclib 400 mg or possibly 600 mg

Experimental: Phase 1b Arm E: - Elacestrant Dihydrochloride 300 mg, 400 mg + Capivasertib 200 mg, 320 mg, 400 mg


Treatment: Drugs: Elacestrant
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days

Treatment: Drugs: Alpelisib
Alpelisib 250 mg or 300 mg once daily in cycles of 28 days

Treatment: Drugs: Everolimus
Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days

Treatment: Drugs: Ribociclib
Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days

Treatment: Drugs: Palbociclib
Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days

Treatment: Drugs: Capivasertib
Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days

Treatment: Drugs: Abemaciclib
Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of DLTs observed during the first cycle
Assessment method [1] 0 0
Number of dose-limiting toxicities during the first cycle
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Estimation of PFS rate at 6 months
Assessment method [2] 0 0
PFS rate for each of the combination arms in patients who received prior ET and CDK4/6i in the metastatic setting
Timepoint [2] 0 0
6 months
Secondary outcome [1] 0 0
Standard PK parameters including AUC0-tau, Cmax, Tmax, and Ctrough
Assessment method [1] 0 0
The plasma PK of elacestrant and each of the combination drugs
Timepoint [1] 0 0
36 months
Secondary outcome [2] 0 0
Overall Response Rate
Assessment method [2] 0 0
Proportion of patients who achieve a best overall response (BOR) of confirmed partial response (PR) or complete response (CR)
Timepoint [2] 0 0
36 months
Secondary outcome [3] 0 0
Duration of Response
Assessment method [3] 0 0
Time from the date of the first documented CR/PR until the first radiological documentation of disease progression or death
Timepoint [3] 0 0
36 months
Secondary outcome [4] 0 0
Clinical Benefit Rate
Assessment method [4] 0 0
Proportion of patients who have the best overall response with a complete response, partial response or stable disease
Timepoint [4] 0 0
36 months
Secondary outcome [5] 0 0
Progression-free survival
Assessment method [5] 0 0
Time from the date of the first dose to the date of the first radiological documentation of disease progression or death, whichever occurs first
Timepoint [5] 0 0
36 months
Secondary outcome [6] 0 0
Overall Survival
Assessment method [6] 0 0
Time from the date of the first dose to the date of death from any cause
Timepoint [6] 0 0
36 months

Eligibility
Key inclusion criteria
1. Patient has signed the informed consent before all study specific activities are conducted.
2. Women or men aged =18 years (or the minimum age of consent in accordance with the local law), at the time of informed consent signature. Female patients may be of any menopausal status.

* Postmenopausal status is defined by:

1. Age =60 years
2. Age <60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) or a follicle-stimulating hormone (FSH) value >40 mIU/mL and an estradiol value<40 pg/mL (140 pmol/L) or in postmenopausal ranges per local reference ranges
3. Documentation of prior surgical sterilization (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, at least 1 month before first dose of trial therapy).
* Premenopausal and perimenopausal women (who do not fit postmenopausal criteria) and men must be concurrently receiving a luteinizing hormone-releasing hormone (LHRH) agonist initiated at least 4 weeks before the start of trial therapy and are planning to continue LHRH agonist treatment during the study treatment.
* For perimenopausal women to be considered of non-childbearing potential, FSH levels must be >40 mIU/ml.
3. Histopathological or cytological confirmed ER+, HER2-, breast cancer, per local laboratory, as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists(CAP) guidelines (Allison et al, 2020, Wolff et al, 2018). Note: In the context of this trial, ER status will be considered positive if =10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry, with or without PGR positivity. .
4. At least 1 not previously irradiated measurable lesion as per RECIST version 1.1 and/or at least 1 lytic or mixed (lytic +sclerotic) bone lesion with identifiable soft tissue components meeting the definition of measurability by RECIST version 1.1 that can be evaluated by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.
5. ECOG performance status of 0 or 1.
6. Patient has adequate bone marrow and organ function, as defined by the following laboratory values:

1. Absolute neutrophil count (ANC) =1.5 × 10^9/L
2. Platelets =100 × 10^9/L
3. Hemoglobin =9.0 g/dL
4. Potassium, sodium, calcium (corrected for serum albumin) and magnesium CTCAE grade =1
5. Creatinine is = 1.5 x ULN or if creatinine is > 1.5 x ULN, then creatinine clearance must be =50 mL/min based on the Cockcroft-Gault formula. Note: C-G formula:

* Creatinine clearance (male) = ([140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72)
* Creatinine clearance (female) = (0.85 × [140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72)
6. Serum albumin =3.0 g/dL (=30 g/L)
7. In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3.0 × ULN. If the patient has liver metastases, ALT and AST = 5 × ULN
8. Total serum bilirubin <1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is =3.0 × ULN or direct bilirubin = 1.5 × ULN.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Active or newly diagnosed CNS metastases, including meningeal carcinomatosis. Note: Patients with stable brain or subdural metastases are allowed if the patient has completed local therapy and was on a stable or decreasing dose of corticosteroids at baseline for management of brain metastasis for at least 4 weeks before starting treatment in this study. The dose must be =2.0 mg/day of dexamethasone or equivalent. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
2. Patients with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement >50%.
3. Prior chemotherapy or elacestrant in the advanced/metastatic setting.
4. Patients with known germline BRCA mutation without prior treatment with a PARP inhibitor before study entry.
5. Prior therapy with elacestrant or other investigational selective estrogen receptor degraders (SERDs), or investigational alike agents such as selective estrogen receptor modulators (SERM), selective estrogen receptor covalent antagonists (SERCANs), complete estrogen receptor antagonists (CERANs), and proteolysis-targeting chimeras (PROTACs), in the metastatic setting. Prior treatment with fulvestrant is not exclusionary as it is an approved medication.
6. Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy. Other malignancies with low risk of recurrence may be considered eligible with Sponsor approval.
7. Uncontrolled significant active infections. • Patients with HBV and/or HCV infection must have undetectable viral load during screening.

• Patients known to be HIV+ are allowed if they have undetectable viral load at baseline.
8. Documented pneumonitis/ILD prior to Cycle 1 Day 1.
9. Major surgery within 28 days before starting trial therapy.
10. Inability to take oral medications, refractory or chronic nausea, gastrointestinal conditions (including significant gastric or bowel resection), history of malabsorption syndrome, or any other uncontrolled gastrointestinal condition that impact the absorption of the study drug.
11. Known intolerance to elacestrant or any of its excipients.
12. Pregnant and breast-feeding women are excluded from the study. In addition, women of childbearing potential are excluded who:

• Within 28 days before starting trial therapy, did not use a highly effective method of contraception.

• Do not agree to use a highly effective method of contraception (Appendix F) or abstain from heterosexual intercourse throughout the entire study period and for 120 days after trial therapy discontinuation.
13. Men or women who do not agree to abstain from donating sperm or ova, or to use a highly effective method of contraception, during the course of the treatment period and for 120 days after the last dose of study treatment.
14. Patient is currently receiving or received any of the following medications prior to first dose of trial therapy:

• Anti-cancer therapy within 14 days (28 days for anticancer antibody based treatment) or 5 half-lives, whichever is shorter.

Please note: Toxicity from prior therapy must be resolved to NCI CTCAE version 5.0 Grade =1, except alopecia and peripheral sensory neuropathy (Grade =2).

• Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 14 days or 5 half-lives, whichever is shorter, (refer to http://medicine.iupui.edu/clinpharm/ddis/ or https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers).

• Herbal preparations/medications within 7 days. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.

• Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.
15. Evidence of ongoing alcohol or drug abuse as assessed by the investigator.
16. Any severe medical or psychiatric condition that, in the Investigator's opinion, would preclude the patient's participation in a clinical study.

Additional Eligibility for the Alpelisib Combination (Phase 1b and Arm A)

Inclusion:

In general, the SmPC of the respective combination drug should be consulted for instructions/restrictions with respect to interactions with concomitant medications.

1. PIK3CA mutation by local laboratory assessment.
2. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

1. Prior therapy with alpelisib or any other PI3K inhibitor.
2. Type 1 diabetes or uncontrolled type 2 diabetes (fasting plasma glucose level of >140 mg/dL [7.7 mmol/L], or glycosylated hemoglobin [HbA1c] level of >6.4%).
3. Known intolerance to alpelisib or any of its excipients.
4. Patient is currently receiving or received drugs known to be a BCRP inhibitor within 14 days or 5 half-lives, whichever is shorter, prior to first dose of trial therapy
5. Patient has ongoing osteonecrosis of the jaw from previous or concurrent treatment with bisphosphonates or denosumab

Additional Eligibility for the Everolimus Combination (Phase 1b and Arm B)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

1. Prior therapy with everolimus.
2. Known intolerance to everolimus or any of its excipients.

Additional Eligibility for the Abemaciclib Combination (Arm C)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

1. Prior therapy with abemaciclib in the advanced or metastatic setting. Adjuvant therapy with abemaciclib is exclusionary if the patient relapsed within the past 12 months.
2. Known intolerance to abemaciclib or any of its excipients.

Additional Eligibility for the Ribociclib Combination (Phase 1b and Arm C)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

1. Prior therapy with ribociclib in the metastatic setting. Prior adjuvant therapy with ribociclib is also exclusionary if the patient relapsed within the past 12 months.
2. Known intolerance to ribociclib or any of its excipients.
3. QTcF values =450 msec.
4. Patients who already have or who are at significant risk of developing QTc prolongation, including patients with:

* Long QT syndrome
* Uncontrolled or significant cardiac disease including recent (6 months) myocardial infarction, congestive heart failure, unstable angina, and brady-arrhythmias
* Electrolyte abnormalities
5. Patient is currently receiving or received drugs known to prolong QT interval within 14 days or 5 half-lives, whichever is shorter, before the first dose of trial therapy.

Additional Eligibility for the Palbociclib Combination (Phase 1b)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

1. Prior therapy with palbociclib in the metastatic setting.
2. Known intolerance to palbociclib or any of its excipients

Additional Eligibility for the Palbociclib Combination (Arm D)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting.

Exclusion:

1. Prior therapy with a CDK4/6i in the metastatic setting.
2. Known intolerance to palbociclib or any of its excipients.

Additional Eligibility for the Abemaciclib Combination (Arm D)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting.

Exclusion:

1. Prior therapy with any CDK4/6i in the metastatic setting.
2. Known intolerance to abemaciclib or any of its excipients.

Additional Eligibility for Ribociclib Combination (Arm D)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting.

Exclusion:

1. Prior therapy with a CDK4/6i in the advanced or metastatic setting.
2. Known intolerance to ribociclib or any of its excipients.
3. QTcF values =450 msec.
4. Patients who already have or who are at significant risk of developing QTc prolongation, including patients with:

* Long QT syndrome
* Uncontrolled or significant cardiac disease including recent (6 months) myocardial infarction, congestive heart failure, unstable angina, and brady-arrhythmias
* Electrolyte abnormalities
5. Patient is currently receiving or received drugs known to prolong QT interval within 14 days or 5 half-lives, whichever is shorter, before the first dose of trial therapy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/12/2028
Actual
Sample size
Target
400
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Macquarie University - Sydney
Recruitment postcode(s) [1] 0 0
2113 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
Rhode Island
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Cordoba
Country [29] 0 0
Argentina
State/province [29] 0 0
La Rioja
Country [30] 0 0
Belgium
State/province [30] 0 0
Anderlecht
Country [31] 0 0
Belgium
State/province [31] 0 0
Charleroi
Country [32] 0 0
Belgium
State/province [32] 0 0
Leuven
Country [33] 0 0
Belgium
State/province [33] 0 0
Sint-Niklaas
Country [34] 0 0
Brazil
State/province [34] 0 0
Goiania
Country [35] 0 0
Brazil
State/province [35] 0 0
Itajai
Country [36] 0 0
Brazil
State/province [36] 0 0
Porto Alegre
Country [37] 0 0
Brazil
State/province [37] 0 0
Sao Paulo
Country [38] 0 0
Czechia
State/province [38] 0 0
Horovice
Country [39] 0 0
Czechia
State/province [39] 0 0
Olomouc
Country [40] 0 0
France
State/province [40] 0 0
Lyon
Country [41] 0 0
France
State/province [41] 0 0
Montpellier
Country [42] 0 0
France
State/province [42] 0 0
Rouen
Country [43] 0 0
France
State/province [43] 0 0
Toulouse
Country [44] 0 0
France
State/province [44] 0 0
Villejuif
Country [45] 0 0
Germany
State/province [45] 0 0
Baden-Wuerttemberg
Country [46] 0 0
Germany
State/province [46] 0 0
Bayern
Country [47] 0 0
Germany
State/province [47] 0 0
Sachsen
Country [48] 0 0
Germany
State/province [48] 0 0
Bottrop
Country [49] 0 0
Germany
State/province [49] 0 0
Dresden
Country [50] 0 0
Germany
State/province [50] 0 0
Essen
Country [51] 0 0
Germany
State/province [51] 0 0
Kassel
Country [52] 0 0
Germany
State/province [52] 0 0
Tübingen
Country [53] 0 0
Hungary
State/province [53] 0 0
Budapest
Country [54] 0 0
Israel
State/province [54] 0 0
Ashdod
Country [55] 0 0
Israel
State/province [55] 0 0
Haifa
Country [56] 0 0
Israel
State/province [56] 0 0
Jerusalem
Country [57] 0 0
Israel
State/province [57] 0 0
Petah Tikva
Country [58] 0 0
Israel
State/province [58] 0 0
Ramat Gan
Country [59] 0 0
Italy
State/province [59] 0 0
Brescia
Country [60] 0 0
Italy
State/province [60] 0 0
Cremona
Country [61] 0 0
Italy
State/province [61] 0 0
Milano
Country [62] 0 0
Italy
State/province [62] 0 0
Napoli
Country [63] 0 0
Italy
State/province [63] 0 0
Pisa
Country [64] 0 0
Italy
State/province [64] 0 0
Rimini
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Seongnam-si
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Seoul
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Ulsan
Country [68] 0 0
Luxembourg
State/province [68] 0 0
Libramont
Country [69] 0 0
Poland
State/province [69] 0 0
Mazowieckie
Country [70] 0 0
Poland
State/province [70] 0 0
Konin
Country [71] 0 0
Poland
State/province [71] 0 0
Poznan
Country [72] 0 0
Poland
State/province [72] 0 0
Lódz
Country [73] 0 0
Spain
State/province [73] 0 0
A Coruña
Country [74] 0 0
Spain
State/province [74] 0 0
Barcelona
Country [75] 0 0
Spain
State/province [75] 0 0
Madrid
Country [76] 0 0
Spain
State/province [76] 0 0
Malaga
Country [77] 0 0
Spain
State/province [77] 0 0
Pozuelo de Alarcon
Country [78] 0 0
Spain
State/province [78] 0 0
Valencia
Country [79] 0 0
Turkey
State/province [79] 0 0
Ankara
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Liverpool
Country [81] 0 0
United Kingdom
State/province [81] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Stemline Therapeutics, Inc.
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Stemline Trials
Address 0 0
Country 0 0
Phone 0 0
1-877-332-7961
Email 0 0
clinicaltrials@menarinistemline.com
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05563220